Premium
Intravesical Evans bacille Calmette‐Guérin for carcinoma in situ of the urinary bladder
Author(s) -
TALIC R.F.,
HARGREAVE T.B.,
BISHOP M.C.,
KIRK D.,
PRESCOTT S.
Publication year - 1994
Publication title -
british journal of urology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.773
H-Index - 148
eISSN - 1464-410X
pISSN - 0007-1331
DOI - 10.1111/j.1464-410x.1994.tb07549.x
Subject(s) - carcinoma in situ , medicine , urology , urinary bladder , carcinoma , urinary system , bcg vaccine , surgery , pathology , tuberculosis
Objective To study the long‐term results of a single 8 week course of intravesical Evans bacillus Calmette‐Guérin (BCG) on carcinoma in situ (CIS) of the urinary bladder. Patients and methods This study reports on 43 patients who each received a single 8 week course of intravesical BCG. Results In spite of the good initial complete response rate of 70%, the long‐term follow‐up was disappointing with half the patients either having recurrence or progression of their disease by 2 years. The patients had a close follow‐up protocol with early radical treatment when disease progressed. The cause specific survival at 5 years was 70%. Conclusion We feel that similar future treatment protocols without maintenance treatment are not justified.